🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Papers like this help pull together the latest developments in our collective understanding of tendon biology which, in turn, help us develop better biological treatments. Thanks Antonion (Tony) Korcari, PhD!

The DermaPrecise Injection System Shown to Produce Consistently High Cell Viability for Cell Therapy Injections. Testing performed by Innovacell shows cell data superior using the DermaPrecise injector vs manual injections. accesswire.com/viewarticle.as… #celltherapy #dermtwitter

How many papers might the new White House public access policy apply to? OSTP estimates 195,000 to 263,000 articles fed funded in 2020. That is ~7% to 9% of the 2.9 million papers published worldwide in 2020. From: p12 of economic analysis to Congress. whitehouse.gov/wp-content/upl…

Great news for science transparency and the democratization of research data!

RepliCel Provides Corporate Update replicel.com/news/replicel-…

We just arrived in Japan! We are meeting with multiple potential investors and partners for all of our products: RCH-01 for regrowing hair, RCS-01 for rejuvenating skin, RCT-01 for repairing tendons,& DermaPrecise for precision injections. CEO Andrew Schutte is busy. Stay tuned.

We are back from our trip to Japan. 🇯🇵 RepliCel is planning another visit to Japan in a few weeks. We are making progress and we won’t stop.

RepliCel’s AGM is scheduled for February 28,2023 at 2 pm PST. It will be held in person at our legal office at Clark Wilson 900-855 West Georgia St. Vancouver BC, & virtually via Zoom. Our President & CEO Andrew Schutte will present alongside the Directors. Hope to see you there!

I’m en route to Canada 🇨🇦 today for RepliCel Life Sciences Inc. AGM and meetings with scientists and business peeps. Of course I am flying by #hairplane ! 🌎🛩️🍁🔬🧫😁

Wrapping up a productive day with ⁦RepliCel Life Sciences Inc.⁩ and ⁦Kevin McElwee⁩. Lots of science and planning for future collaborations.

Thank you for attending our AGM! The two big takeaways that our CEO, Andrew Schutte, expressed are: 1) Obtaining a 510k approval for DermaPrecise this year 2) Concluding our ongoing arbitration proceedings, the hearing begins May 29th.

RepliCel notes that the proceedings are ongoing and will further elaborate as circumstances allow. RepliCel is committed to commercializing RCH-01! RepliCel aims to have a fully calibrated commercial grade device in the coming months. We look forward to updating the market as

In response to investor inquiries, RepliCel notes that the arbitration proceedings with Shiseido are ongoing. RepliCel respects the confidentiality rules of the ICDR and will provide material updates as they become available. We thank investors for their ongoing interest!

Shareholders are invited to the RepliCel AGM scheduled for September 22 at 2 p.m. PST. We hope you can join in person at Clark Wilson LLP located at 900 – 885 West Georgia Street Vancouver, BC V6C 3H1 or see website before meeting for online access.

RepliCel Shareholders are invited to attend the AGM located at Clark Wilson LLP 900 – 885 West Georgia Street Vancouver, BC V6C 3H1 on September 22 at 2 PM Pacific. The AGM Zoom Link and Materials are posted on the RepliCel website located at replicel.com

RepliCel signs Letter of Intention (Asset Purchase) replicel.com/news/letter-of…